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Abstract
Background: Osteoarthritis (OA) is the most common degenerative arthropathy. Load-bearing joints such as knee and 
hip are more often affected than spine or hands. The prevalence of gonarthrosis is generally higher than that of 
coxarthrosis.
Because no cure for OA exists, the main emphasis of therapy is analgesic treatment through either mobility or
medication. Non-pharmacologic treatment is the first step, followed by the addition of analgesic medication, and
ultimately by surgery.
The goal of non-pharmacologic and non-invasive therapy is to improve neuromuscular function, which in turn both
pr events f ormation of and dela ys pr og r ession of O A. A modification of con v entional ph ysiotherap y , whole body
vibration has been successfully employed for several years. Since its introduction, this therapy is in wide use at our
facility not only for gonarthrosis, but also coxarthrosis and other diseases leading to muscular imbalance.
Methods/Design: This study is a randomized, therapy-controlled trial in a primary care setting at a university hospital. 
Patients presenting to our outpatient clinic with initial symptoms of gonarthrosis will be assessed against inclusion and 
exclusion criteria. After patient consent, 6 weeks of treatment will ensue. During the six weeks of treatment, patients 
will receive one of two treatments, conventional physiotherapy or whole-body-vibration exercises of one hour three 
times a week. Follow-up examinations will be performed immediately after treatment and after another 6 and 20 
weeks, for a total study duration of 6 months. 20 patients will be included in each therapy group.
Outcome measurements will include objective analysis of motion and ambulation as well as examinations of balance
and isokinetic force. The Western Ontario and McMaster Universities Arthritis Index and SF-12 scores, the patients'
overall status, and clinical examinations of the affected joint will be carried out.
Discussion: As new physiotherapy techniques develop for the treatment of OA, it is important to investigate the 
effectiveness of competing strategies. With this study, not only patient-based scores, but also objective assessments 
will be used to quantify patient-derived benefits of therapy.
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Background
Osteoarthritis (OA) is the most common degenerative
arthropathy. Patients affected by this disease suffer from
numerous sequelae, and costs of treatment are high
enough to have socio-economic relevance [1-3]. Preva-
lence of OA rises steadily with advancing age, and women
are more typically affected than men [4-6]. Load-bearing
joints in particular such as knee and hip are more often
affected than spine or hands. Prevalence and incidence of
clinical symptoms, and radiologically confirmed gonar-
throsis range from 1.6 - 9.4% and 240 out of 100.000 [7,8].
The prevalence of gonarthrosis is usually higher than that
of coxarthrosis, particularly in middle-aged patients [9].
Gonarthrosis is commonly defined as a degenerative,
non-infectious disease of the knee joint. Morphologically,
arthrosis is characterized by progressive loss of cartilage,
sclerosis of the subchondral osseous structures, and par-
tial involvement of the synovia [10].
The cardinal symptom of gonarthrosis is pain that is
usually activity-related and is intensified by weight-bear-
ing. Initially, the pain has an episodic character and can
be relieved by rest, but with disease progression the pain
intensifies and becomes more constant.
When patients present with severe pain, motor impair-
ment, or joint effusion, the arthrosis is refered to as acti-
vated [9].
Further clinical signs of gonarthrosis are crepitus, pal-
pable osteophytes, coarsening of joint contour, varus or
valgus deformity, and joint instability. Because almost
40% of patients with OA are asymptomatic, Kellgren and
Lawrence introduced a set of radiologic criteria in 1957.
A more specific classification was developed in 1986 by
the American Rheumatism Association (ARA), now
called the American College of Rheumatology (ACR).
These criteria have been validated and include several
clinical and radiographic examinations [11]. As long as no
cure exists, the main emphasis of OA treatment is analge-
sia, through either increasing mobility or medication
administration. Initially, non-pharmacologic therapies
are attempted, followed by the addition of medication,
and ultimately surgical intervention [12-14].
For non-pharmacologic and non-invasive therapy, the
goal of treatment is to optimize neuromuscular function,
which acts both to prevent as well as to delay progression
of the disease [15]. Muscle training to correct imbalance,
relieve the joints, and invigorate surrounding structures
is essential to this therapy. The goals of treatment are
twofold--to provide analgesia for patients, but also to
delay the need for pharmacotherapy. Because of this, cer-
tain enhancements to conventional physiotherapy have
been introduced. One such modification is the use of
whole body vibration devices, available since 2001. For
this, patients stand on a vibrating plate with adjustable
amplitude and frequency. The idea is to activate counter-
regulatory contractions through the distension of
reflexes, which leads to fine-tuning of the neuromuscular
spindles. Since its introduction, this therapy has been
used widely at our facility not only for gonarthrosis, but
also coxarthrosis and other diseases causing muscular
imbalance.
Various studies have identified a number of results after
the use of whole body vibration. For instance, improve-
ments in muscular strength and coordination as well as
an arrest of muscle atrophy have been observed [16,17]. It
also improves osseous metabolism [18].
The general assumption is that whole body vibration
causes minor stress of the joint affected by OA. Examin-
ing women with gonarthrosis, Trans et al. found that
whole body vibration led to increased muscle formation
and improved proprioception [19]. Male patients have
not yet been assessed.
Clearly, an investigation of the use of whole body vibra-
tion in men alone would be an interesting clinical study.
However, because the success of treatment has so far
been measured mostly using questionnaires, we also
thought it expedient to introduce validated question-
naires like WOMAC and SF-12, and also assess balance,
mobility, and general function of the lower legs. By these
means, we should achieve some outlook of this technique
from a long-term perspective.
Objective
The objective of this study is to compare the effects of
physiotherapy alone or physiotherapy conducted with a
whole body vibration device for the treatment of mild to
moderate symptomatic gonarthrosis. The study would be
conducted in a primary care setting at a university hospi-
tal. Questionnaire assessments relating to clinical out-
come as well as objective analysis of ambulation and
balance will be performed.
Methods and Design
The study is designed as a randomized, therapy-con-
trolled trial in a primary care setting at a university hospi-
tal. Patients presenting to our outpatient clinic with early-
stage gonarthrosis will be assessed against study inclusion
and exclusion criteria. After patient informed consent, 6
weeks of therapy will ensue. Follow-up examinations will
be performed immediately after treatment and after
another 6 and 20 weeks, for a total study duration of 6
months.
Source of funding for the study is the "Deutsche
Arthrose Hilfe e.V.", a non-profit patients support group
promoting scientific research on osteoarthritis. Funding
has been used for the conduction of therapy, sample size
calculations, Womac and SF-12 licenses and for equip-
ment acquisition.Stein et al. BMC Musculoskeletal Disorders 2010, 11:128
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Experimental research in this trial will be performed
with the approval of the ethics committee of the medical
faculty of the University of Cologne under the reference
number 10-006. Research carried out in the trial will be in
compliance with the Helsinki Declaration.
Participants and recruitment
Patients aged 30 - 80 years presenting to our outpatient
clinic with symptoms of early-stage gonarthrosis are eli-
gible for the trial. Further inclusion criteria are summa-
rized in the appendices.
Patients participating in parallel interventional studies
as well as patients suffering from severe gonarthrosis are
excluded from this study. The exclusion criteria are sum-
marized in the appendices.
Interventions
During the six weeks of treatment, patients will receive
one of two treatments:
j Conventional physiotherapy
j Whole-body-vibration exercises
Conventional physiotherapy
Patients in this study group will attend physiotherapeutic
exercise sessions of one hour three times a week for six
weeks. The sessions consist of aerobic and muscle
strengthening as well as coordination exercises. Patients
will practice activities of daily living. The goals of these
exercises are to improve joint stability, optimize knee and
ankle proprioception, and advance neuromuscular inner-
vation of the lower extremity and thereby suppress patho-
logic motion patterns. This should lead to optimized
mobility, increased stability, and thus more endogenous
analgesia of the affected joint.
Whole body vibration
Patients in this study group will attend whole body vibra-
tion exercise sessions of one hour three times a week for
six weeks, using the Galileo® Fitness device. Initial train-
ing sessions will focus on patient acclimatization, and
afterwards improved on muscular capacity and body
coordination. During exercise sessions, patients will do 6
training cycles of 3 minutes each. The goals of this treat-
ment are improved proprioception of the ankle and knee
joints, as well as optimization of neuronal reactivation of
the muscles and thereby improved joint stability. This
should also increase endogenous analgesia.
Outcome measures and assessments
The primary outcome measure is the patients' evaluation
of improvement on the visual analogue scale of the
WOMAC indices for pain and activities of daily life, com-
paring baseline and post-treatment. The secondary out-
come measures summarized in the appendices will also
be assessed at baseline and after 6, 12, and 26 weeks.
The WOMAC index is a validated patient question-
naire used to evaluate coxarthrosis and gonarthrosis by
evaluating symptoms and motor impairment in daily life
[20,21]. Use of this index in clinical studies is recom-
mended by OARSI and EMEA and has received approval
from many studies [20].
Functional motion analysis, the Modified Clinical Test
of Sensory Interaction in Balance, the Tandem Walk Test,
and the Rhythmic Weight Shift Test will be performed
using the Leonardo Mechanography Gangway (Novotec
Inc., Pforzheim, Germany) and the Balance Master Anal-
ysis System (Neurocom Inc., Clackamas, USA). These
will provide reliable data on essential parts of ambulation,
e.g. stride length, speed of movement, shifting of balance
point, force, power, and workload.
Overall patient status is recommended as a secondary
endpoint by EMEA and GREES [11,22]. According to the
recommendations of Bellamy et al. [23], study partici-
pants will be asked questions regarding symptoms of the
treated and other joints as well as subjective health status.
The Osteoarthritis Research Society International
(OARSI) and the Outcome Measures in Rheumatology
Committee (OMERACT) have developed common crite-
ria to assess patient response to therapy for OA [24,25].
The criteria assess improvements of pain, affected joint
function, as well as overall patient status.
The SF-12 score uses subjective patient responses to
measure success of therapy and thereby evaluate quality
of life. SF-12 is the abbreviated version of the SF-36
Health Survey and contains 12 items representing 8
dimensions of physical and mental fitness. In our study,
the validated German translation will be used [26].
The clinical examination of the knee joint will assess
intraarticular effusion as well as range of motion.
Finally, the isokinetic force of the knee will be measured
using a calibrated "Biodex System 3" (Biodex Medical Sys-
tems Inc., Shirley, NY, USA). The maximum isometric
force will be measured first by extending and then by
flexing the knee.
Sample size
It is assumed that the standard deviation of the therapeu-
tic effects is σ = 19 mm. Furthermore, no difference
between the effects of the different therapy groups is
expected. The relevant difference in the scores used for
primary outcome is defined as 20 mm. By postulating
80% power using a level of significance of 2.5%, a total
number of 31 test patients is needed. When considering a
potential drop-out of 4 patients per treatment group, a
total of 40 patients will be included into the study.
Randomization
The randomization of patients into the groups of inter-
vention and control is achieved by using blocks of ran-Stein et al. BMC Musculoskeletal Disorders 2010, 11:128
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domized size. The groups itself are furthermore stratified
into gender groups. Technically a locked container with
sequentially numbered envelopes is used. The random
allocation sequence was generated by the institute of
medical statistics, informatics and epidemiology of the
university conducting the trial. Enrollment and random-
ization will be executed by the investigator.
Discussion
OA remains a major disease in the field of musculoskele-
tal disorders. Patients presenting with early-stage OA are
typically treated with non-curative therapies such as anal-
gesics. Until a cure is found, therapy focused on the roots
of symptomatic complaints should be used as well to
bridge the gap between disease onset and operative ther-
apy such as partial or total joint replacement. Conven-
tional physiotherapy is well established as one alternative
for this bridge. However, new treatment methods like
whole body vibration training also seek to improve mus-
cle coordination and thereby optimize affected joint load-
ing. Because both conventional physiotherapy and whole
body vibration have co-existed for several years, we can
now compare them in an attempt to optimize non-opera-
tive treatment for patients with OA.
Appendix
Inclusion criteria:
- Age 30 - 80 years
- Body weight less than or equal to 160 kg
- Body-Mass-Index less than 40 kg/m²
- Outpatient
- Legal competence
- Signed informed consent
- Uni- or bilateral gonarthrosis according to ACR cri-
teria
- WOMAC-pain index (visual analogue scale) of 30-
70 mm
- Gonarthrosis stage II-III according to Kellgren and 
Lawrence
Exlusion criteria:
- Participation in parallel interventional studies
- Bilateral gonarthrosis with WOMAC Pain index ≥ 
70 mm
- Dominant femoro-patellar gonarthrosis
- Previous surgery during the past 6 months (excep-
tion: meniscus surgery: past 3 months)
- Injury of the study joint during the last 6 months
- Secondary rheumatoid or septic arthrosis or sys-
temic diseases affecting the study joint
- Activated gonarthrosis with intraarticular effusion
- Body weight > 160 kg or body mass index > 40 kg/m²
- Analgesic therapy with steroidal drugs
- Physiotherapy of the lower extremities during the 
past 6 weeks
- Existing endoprothesis in the lower extremities
Secondary outcome measures:
- Functional motion analysis (Walk Across Test)
- Modified Clinical Test of Sensory Interaction in Bal-
ance
- Tandem Walk Test
- Rhythmic Weight Shift Test
- WOMAC® global index
- Overall patient status
- Response using the criteria of OMERACT-OARSI
- Quality of life measured by SF-12®
- Clinical examination of the knee joint
- Isokinetic measurement of forces in the knee joint
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